The impact of VKORC1-1639 G>A polymorphism on the maintenance dose of oral anticoagulants for thromboembolic prophylaxis in North India: A pilot study

Indian Journal of Human Genetics

Volumn 17, Issue SUPPL. 1, 2011, Pages

  Rathore, S ^a   Agarwal, S ^a   Pande, S ^a   Mittal, T ^a   Mittal, B ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Allele frequency; drug dose; genotype; polymorphism; VKORC1

Indexed keywords

ACENOCOUMAROL; ACITROM; ANTICOAGULANT AGENT; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K GROUP;

ARTICLE; CLINICAL ARTICLE; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENOTYPE; HEART VALVE REPLACEMENT; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INDIA; MAINTENANCE THERAPY; MALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOEMBOLISM;

EID: 79956136096     PISSN: 09716866     EISSN: 1998362X     Source Type: Journal    
DOI: 10.4103/0971-6866.80360     Document Type: Article

References (12)

1. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study. Lancet 1996;348:423-8. (Pubitemid 26267872)
2. Fihn SD, Callahan CM, Martin DC, McDonnell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996;124:970-9.
3. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, et al. Interindividual variability in sensitivity to warfarin: Nature or nurture? Clin Pharmacol Ther 2001;70:159-64.
4. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: Significance of vitamin K epoxide reductase inhibition. Biochem 1978;17:1371-7. (Pubitemid 8330368)
5. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004;6974:541-4. (Pubitemid 38209111)
6. Lee MT, Chen CH, Chuang HP, Lu LS, Chou CH, Chen YT, et al. VKORC1 haplotypes in five East-Asian populations and Indians. Pharmacogenomics 2009;10:1609-16.
7. Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, Guo JY, et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 2006;79:197-205.
8. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106. (Pubitemid 40720733)
9. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
10. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 2005;106:2329-33. (Pubitemid 41510803)
11. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5. (Pubitemid 40202029)
12. Kamali F, Wynne H. Pharmacogenetics of warfarin. Annu Rev Med 2010;61:63-75.